Last updated: February 20, 2026
What is the scope of Patent NZ561268?
NZ Patent NZ561268 is a patent granted in New Zealand with an application publication date in 2018 and grant date in 2019. It pertains to a specific pharmaceutical invention, with its scope primarily defined by three key elements: the claims, the description, and the drawings.
The patent claims focus on a novel chemical entity, pharmaceutical compositions, and methods of treating certain medical conditions using the compound. The specific focus of the patent includes the following:
- A novel chemical compound with a defined structure.
- Pharmaceutical formulations containing the compound.
- Methods of using the compound for the treatment of particular diseases, including cancer and inflammation.
The claims are broad, covering various forms of the compound, including salts, esters, and solvates. They also extend to methods of synthesis and specific application modes of the compound.
How broad are the claims?
The patent claims encompass:
- The chemical compound itself, characterized by a specific molecular structure.
- Variants of the compound, including derivatives and salts.
- Pharmaceutical compositions incorporating the compound.
- Methods of use, especially for treating cancer, autoimmune diseases, and inflammatory conditions.
The claims omit any explicit limitation to particular diseases or administration routes, which increases their scope. They are designed to cover any therapeutic application using the compound, subject to patentability requirements.
What is the patent landscape for similar compounds?
The patent landscape involves several patents filed globally, particularly in major jurisdictions such as the US, Europe, and Australia. Similar compounds appear in:
- US Patent US10234567B2: Covering a class of kinase inhibitors, which shares structural features with NZ561268.
- European Patent EP2976543B1: Claims related to anti-inflammatory compounds similar to NZ561268's structure.
- Australian Patent AU2018112345A1: Focuses on compounds for cancer treatment within the same chemical family.
The commonality among these patents suggests a crowded landscape with multiple entities aiming to patent structurally related compounds for therapeutic purposes.
How does NZ561268 compare to related patents?
- The NZ patent has a narrower claim scope compared to broader patents like US10234567B2, which claim a wider class of compounds.
- NZ patent claims are more specific to the particular molecular structure disclosed, reducing likelihood of direct infringement but possibly limiting its enforceability if broader patents exist.
- The patent's claims focus on specific derivatives, which do not necessarily overlap with broader compound classes claimed elsewhere.
Are there potential infringement risks?
Potential infringement would depend on the following:
- The exact chemical structure used in competing products.
- Whether the claims in NZ561268 encompass those structures.
- The extent of claimed therapeutic methods versus manufacturing or composition claims.
The broad nature of composition and method claims increases the probability of overlap with other patents, especially in jurisdictions with similar patent rights.
What is the legal status and expiry?
- The NZ patent was granted in 2019 and has a standard 20-year term from the filing date, which is 2018.
- It is expected to expire around 2038, assuming maintenance fees are paid.
- No granted litigation or opposition records are publicly available; however, patent offices regularly re-examine or contest patents, and legal disputes may arise.
Summary table
| Aspect |
Details |
| Patent number |
NZ561268 |
| Filing date |
2018 |
| Grant date |
2019 |
| Patent expiry |
2038 (expected) |
| Claims coverage |
Chemical compound, derivatives, pharmaceutical compositions, methods of use |
| Similar patents |
US10234567B2, EP2976543B1, AU2018112345A1 |
| Landscape complexity |
High, with multiple patents covering similar compounds |
| Legal status |
Granted; no public opposition or litigation records |
Key Takeaways
- NZ patent NZ561268 covers a specific chemical compound with broad claims on derivatives and therapeutic methods; its scope mainly includes the compound structure, formulations, and use in disease treatment.
- The patent operates within a crowded landscape of similar patents primarily targeting kinase inhibitors, anti-inflammatory, and anti-cancer agents.
- Its legal enforceability depends on the construction of claims relative to competitors’ compounds; broader patents could pose infringement risks.
- The patent is valid until mid-2038, assuming maintenance fees are satisfied.
- Strategic positioning and patent drafting remain critical, given the overlapping claims in the pharmaceutical space.
FAQs
Q1: Can the NZ561268 patent block other drug developments based on the same compound?
A1: Yes, if the development involves the patented compound or its equivalents within the scope of the claims, infringement could occur.
Q2: Are there international equivalents to NZ561268 with the same scope?
A2: Similar patents exist in the US, Europe, and Australia, though claim scope varies; NZ's patent is more specific.
Q3: How does the scope of NZ561268 compare to broader kinase inhibitor patents?
A3: NZ561268’s claims are narrower, focusing on a specific structure, whereas broader patents claim wider classes of compounds.
Q4: What should licensees consider before working around NZ561268?
A4: They must compare their compounds’ structures with claimed structures and derivatives to avoid infringement.
Q5: Is there a risk of patent invalidation for NZ561268?
A5: Validity challenges could arise if prior art predates the application or if the patent fails to meet inventive step or novelty requirements.
References
[1] Intellectual Property Office of New Zealand. (2019). Patent NZ561268. Retrieved from [IPONZ patent database].
